VASOPRESSIN by Cipla is v1 receptors on vascular smooth muscle coupled to the gq/11-phospholipase c-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. First approved in 2023.
Drug data last refreshed 6h ago
V1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V2 receptors which are coupled to adenyl cyclase. 12.2…
Worked on VASOPRESSIN at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Intranasal Vasopressin Treatment in Children With Autism
The Effect of Vasopressin on Glucose Regulation